Nasdaq · Healthcare

MAXCYTE, INC. (MXCT)

As-reported financials and recent SEC filings for MAXCYTE, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$21.0M

Net income

$-44.6M

Net margin

—

Diluted EPS

$-0.42

ROE

-26.0%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$21.0M	$22.2M	$41.3M	$28.7M	$21.6M
Gross profit	$14.7M	$15.1M	$36.5M	$23.6M	$17.9M
Operating income	$-51.9M	$-51.2M	$-48.3M	$-27.4M	$-18.2M
Net income	$-44.6M	$-41.1M	$-37.9M	$-23.6M	$-19.1M
Diluted EPS	$-0.42	$-0.39	$-0.37	$-0.23	$-0.21

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-22

42026-06-22

42026-06-22

42026-06-22

42026-06-22

42026-06-22

42026-06-22

42026-06-22

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on MXCT

Search MAXCYTE, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.